Compare ETSY & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETSY | SYRE |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.5B |
| IPO Year | 2015 | 2015 |
| Metric | ETSY | SYRE |
|---|---|---|
| Price | $69.26 | $69.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 12 |
| Target Price | $62.50 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 2.7M | 804.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $441,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.44 | N/A |
| P/E Ratio | $116.22 | ★ N/A |
| Revenue Growth | ★ 20.90 | N/A |
| 52 Week Low | $44.00 | $13.93 |
| 52 Week High | $76.52 | $78.80 |
| Indicator | ETSY | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 68.13 | 47.46 |
| Support Level | $67.62 | $65.93 |
| Resistance Level | $70.88 | $76.15 |
| Average True Range (ATR) | 2.37 | 3.74 |
| MACD | 0.84 | -1.03 |
| Stochastic Oscillator | 91.30 | 32.71 |
Founded in 2005, Etsy operates a leading global marketplace, connecting roughly 87 million active buyers and 6 million sellers of unique, handmade, and vintage goods. In fiscal 2025, the firm generated $2.9 billion in revenue and almost $12 billion in gross merchandise sales. The firm monetizes its marketplace primarily through transaction fees and advertising, with core categories spanning homeware, jewelry, apparel, and craft supplies. The US drives 74% of sales, though its core geographic reach extends to the UK, Germany, Canada, and Australia.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.